Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News

News : $PAGE_TITLE
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
The feature you requested does not exist. However, we suggest the following feature:

Opthea : Final Director's Interest Notice - GK

share with twitter share with LinkedIn share with facebook
10/23/2020 | 01:45am EDT

Appendix 3Z

Final Director's Interest Notice

Rule 3.19A.3

Appendix 3Z

Final Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity: Opthea Limited

ABN: 32 006 340 567

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director

Geoffrey Kempler

Date of last notice

19 March 2019

Date that director ceased to be director

12 October 2020

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities

2,000,000 unquoted options to purchase ordinary shares at an exercise price of $0.48, expiring on 7 March 2021 granted under the Non-Executive Directors Share and Option Plan (NED plan).

1,500,000 unquoted options to purchase ordinary shares at an exercise price of $0.855, expiring on 29 November 2022 granted under the NED plan.

  • See chapter 19 for defined terms. 11/3/2002

Appendix 3Z Page 1

Appendix 3Z

Final Director's Interest Notice

Part 2 - Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest

Note: Provide details of the circumstances giving rise to the relevant interest

Sandhurst Trustees Ltd: the registered holder as nominee on behalf of Geoffrey Kempler as beneficiary.

Baywick Pty Ltd: Geoffrey Kempler is a substantial shareholder.

Number & class of securities

897,960 fully paid ordinary shares

3,000 fully paid ordinary shares

Part 3 - Director's interests in contracts

Detail of contract

N/A

Nature of interest

N/A

Name of registered holder

N/A

(if issued securities)

No. and class of securities to which

N/A

interest relates

+ See chapter 19 for defined terms.

Appendix 3Z Page 2

11/3/2002

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Opthea Limited published this content on 23 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 October 2020 05:44:03 UTC


share with twitter share with LinkedIn share with facebook
Latest news
01:45aOPTHEA : Final Director's Interest Notice - GK
PU
01:45aOPTHEA : Becoming a substantial holder
PU
01:45aINTERIM REPORT JAN–SEP 2020 : Continued increase in income from property management and a strong position for Wihlborgs
PU
01:45aAÉROPORTS DE PARIS SA : Consolidated revenue over the first 9 months of 2020 impacted by the crisis linked to the CoVid-19 epidemic
GL
01:45aNICOX S A : Selects Development Candidate in a New Class of NO-mediated Intraocular Pressure (IOP) Lowering Agents
PU
01:45aTHULE () : interim report, third quarter, July–September 2020
AQ
01:45aORIOLA OYJ : Corporation's Interim report 1 January–30 September 2020
PU
01:45aAÉROPORTS DE PARIS SA : Consolidated revenue over the first 9 months of 2020 impacted by the crisis linked to the CoVid-19 epidemic
AQ
01:45aKLEPIERRE : Business review for the first nine months of 2020
PU
01:45aNOVARTIS : announces European Medicines Agency (EMA) has granted orphan drug designation for iptacopan (LNP023) in IgA nephropathy (IgAN)
PU
Latest news